Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer.
Antigen Presentation
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Carcinoma, Ovarian Epithelial
/ genetics
Cell Line, Tumor
Cohort Studies
DNA Methylation
Endopeptidases
Female
Gelatinases
/ metabolism
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
/ immunology
Histocompatibility Antigens Class I
/ metabolism
Humans
Machine Learning
Membrane Proteins
/ metabolism
Multigene Family
Ovarian Neoplasms
/ genetics
Prognosis
RNA-Seq
Serine Endopeptidases
/ metabolism
Stromal Cells
/ metabolism
Transforming Growth Factor beta
/ metabolism
Tumor Microenvironment
/ immunology
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
04 11 2020
04 11 2020
Historique:
received:
04
10
2019
accepted:
12
10
2020
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Close proximity between cytotoxic T lymphocytes and tumour cells is required for effective immunotherapy. However, what controls the spatial distribution of T cells in the tumour microenvironment is not well understood. Here we couple digital pathology and transcriptome analysis on a large ovarian tumour cohort and develop a machine learning approach to molecularly classify and characterize tumour-immune phenotypes. Our study identifies two important hallmarks characterizing T cell excluded tumours: 1) loss of antigen presentation on tumour cells and 2) upregulation of TGFβ and activated stroma. Furthermore, we identify TGFβ as an important mediator of T cell exclusion. TGFβ reduces MHC-I expression in ovarian cancer cells in vitro. TGFβ also activates fibroblasts and induces extracellular matrix production as a potential physical barrier to hinder T cell infiltration. Our findings indicate that targeting TGFβ might be a promising strategy to overcome T cell exclusion and improve clinical benefits of cancer immunotherapy.
Identifiants
pubmed: 33149148
doi: 10.1038/s41467-020-19408-2
pii: 10.1038/s41467-020-19408-2
pmc: PMC7642433
doi:
Substances chimiques
Histocompatibility Antigens Class I
0
Membrane Proteins
0
Transforming Growth Factor beta
0
Endopeptidases
EC 3.4.-
Serine Endopeptidases
EC 3.4.21.-
fibroblast activation protein alpha
EC 3.4.21.-
Gelatinases
EC 3.4.24.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5583Références
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Immunogenetics. 1990;31(4):245-52
pubmed: 1691737
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Nat Rev Urol. 2016 Jul;13(7):420-31
pubmed: 27324121
Cell. 2017 Aug 24;170(5):927-938.e20
pubmed: 28841418
J Immunol. 1988 Jun 15;140(12):4217-23
pubmed: 3131428
J Immunother Cancer. 2018 Jul 17;6(1):75
pubmed: 30012210
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
J Natl Cancer Inst. 2013 Aug 21;105(16):1172-87
pubmed: 23852952
J Cell Sci. 2003 May 15;116(Pt 10):1863-73
pubmed: 12692188
PLoS Comput Biol. 2013;9(8):e1003118
pubmed: 23950696
Clin Cancer Res. 2016 Feb 15;22(4):813-20
pubmed: 26880610
Clin Cancer Res. 2016 Apr 15;22(8):1865-74
pubmed: 27084740
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
F1000Res. 2013 Dec 04;2:264
pubmed: 24701342
Cell Rep. 2020 Apr 14;31(2):107502
pubmed: 32294438
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Clin Cancer Res. 2014 Feb 1;20(3):764-75
pubmed: 24240112
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Nat Biotechnol. 2015 Nov;33(11):1152-8
pubmed: 26372948
Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):E8151-E8158
pubmed: 27911817
Epigenetics. 2014 Nov;9(11):1461-72
pubmed: 25470663
Blood. 2011 Jul 14;118(2):330-8
pubmed: 21551236
Nat Genet. 2020 Jun;52(6):582-593
pubmed: 32483290
Nat Med. 2018 Oct;24(10):1550-1558
pubmed: 30127393
Front Immunol. 2017 Dec 08;8:1617
pubmed: 29276510
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
Lancet Oncol. 2015 Aug;16(8):928-36
pubmed: 26115797
J Biol Response Mod. 1990 Apr;9(2):113-26
pubmed: 2111373
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72
pubmed: 12011421
Int Immunol. 2016 Jul;28(7):339-48
pubmed: 27055470
Immunology. 1995 Oct;86(2):263-9
pubmed: 7490128
Nucleic Acids Res. 2013 Apr;41(7):e90
pubmed: 23476028
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
Cancer Discov. 2018 Dec;8(12):1518-1528
pubmed: 30442708
Genomics. 2011 Oct;98(4):288-95
pubmed: 21839163
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
JAMA Oncol. 2017 Dec 1;3(12):e173290
pubmed: 29049607
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Bioinformatics. 2010 Apr 1;26(7):873-81
pubmed: 20147302
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cell. 2018 Jun 14;173(7):1755-1769.e22
pubmed: 29754820
Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9944-8
pubmed: 8234339
Nat Commun. 2018 Sep 24;9(1):3868
pubmed: 30250229
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
J Immunother Cancer. 2017 Aug 15;5(1):68
pubmed: 28807024
J Immunother Cancer. 2018 Jun 4;6(1):47
pubmed: 29866156
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Genome Biol. 2014 Dec 03;15(12):503
pubmed: 25599564
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Cancers (Basel). 2019 May 14;11(5):
pubmed: 31091744
Clin Cancer Res. 2014 Apr 15;20(8):2080-91
pubmed: 24573554
J Biol Chem. 2015 Oct 30;290(44):26562-75
pubmed: 26381407
Methods Mol Biol. 2016;1418:283-334
pubmed: 27008021
Genome Biol. 2017 Nov 15;18(1):220
pubmed: 29141660
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
J Clin Invest. 2013 Jan;123(1):517-25
pubmed: 23257362
Oncotarget. 2017 Dec 19;9(3):4120-4133
pubmed: 29423109
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308